Clinical Insights

Clinical Insights: April 6, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Tlando™ (testosterone) Capsules – New Drug Approval – March 28, 2022 – Antares Pharma, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration granted final…

Read More...

Clinical Insights: March 30, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) and Locametz® (gallium Ga 68 gozetotide – New Drug Approval and New Diagnostic Approval – March 23, 2022 – The Food and Drug…

Read More...

Clinical Insights: March 23, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Ztalmy® (ganaxolone) Oral Suspension – New Drug Approval – March 18, 2022 – FDA has approved Ztalmy® (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder…

Read More...

Clinical Insights: March 15, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Lynparza® (Olaparib) Tablets – New Drug Approval – March 11, 2022 –  The Food and Drug Administration approved olaparib (Lynparza®, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult…

Read More...

Clinical Insights: March 9, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Carvykti™ (ciltacabtagene autoleucel) – New Orphan Drug Approval – February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA)…

Read More...

Clinical Insights: March 1, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval NephroScan™ (technetium Tc 99m succimer) Injection Kit – New Diagnostic Approval – February 22, 2022 – Theragnostics announces that NephroScan™, its radiodiagnostic imaging drug used as an aid for…

Read More...

Clinical Insights: February 23, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Pyrukynd® (mitapivat) Tablets – New Drug Approval – February 17, 2022 – FDA has approved Pyrukynd® (mitapivat) tablets to treat hemolytic anemia (a disorder in which red blood cells…

Read More...

Clinical Insights: February 8, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Enjaymo™ (sutimlimab-jome) Injection – New Drug Approval – February 4, 2022 – FDA has approved Enjaymo™ (sutimlimab-jome) infusion to decrease the need for red blood cell transfusion due…

Read More...

Clinical Insights: February 1, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Vabysmo™ (faricimab-svoa) Intravitreal Injection – New Drug Approval – January 28, 2022 – Roche announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for…

Read More...

Clinical Insights: January 26, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Ryaltris™ Nasal Spray – New Drug Approval – January 14, 2022 – Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced that its fully owned subsidiary Glenmark…

Read More...

Clinical Insights: January 19, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Cibinqo® (abrocitinib) Tablets – New Drug Approval – January 14, 2022 – Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved Cibinqo® (abrocitinib),…

Read More...

Clinical Insights: January 11, 2022

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug Approval Advancing Health Through Innovation: New Drug Therapy Approvals 2021 – January 2022 – Welcome to FDA’s Center for Drug Evaluation and Research’s (CDER) annual report, Advancing Health Through…

Read More...